Patients with type 2 diabetes who initiate glucagon-like peptide 1 receptor agonists or dipeptidyl peptidase 4 inhibitors are at a significantly higher risk for biliary disease compared with those who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback